Psychopharmacology and Psychiatry Updates

In this episode, we explore how a psychodynamic approach can shed light on treatment-resistant cases. Can understanding a patient's psychological dynamics be the key to unlocking better outcomes? Faculty: David Mintz, M.D. Host: Richard Seeber, M.D. Learn more about our memberships hereEarn 1.75 CME: Psychodynamic Psychopharmacology: From Biomedical Approaches to Patient RelationshipsUnderstanding the Problem of Treatment Resistance

In this episode, we explore the fascinating connection between ADHD, pain sensitivity, and methylphenidate treatment in children. Could methylphenidate help reduce pain sensitivity in pediatric ADHD patients? Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership hereEarn 0.5 CMEs: CAP Smart Takes Vol. 17Effect of Methylphenidate on Pain Perception Thresholds in Children With ADHD

In this episode, we dive into the complex world of treating insomnia in patients with major depressive disorder. What's the best approach to help these patients find restful sleep and improve their mood? Join us as we explore a range of strategies, from medication to behavioral interventions. Faculty: Amit Chopra, M.D. Host: Richard Seeber, M.D. Learn more about our memberships hereEarn 1.25 CME: Navigating Insomnia in Major Depressive Disorder: Advances in ManagementTreatment Strategies for Managing Insomnia in MDD

In this episode, we explore the latest pharmacologic interventions for managing insomnia in patients with major depressive disorder. Can dual orexin receptor antagonists, melatonin agonists, and low-dose doxepin provide relief for those struggling with sleep? Join us as we discuss the advances in treating insomnia and depression. Faculty: Amit Chopra, M.D. Host: Richard Seeber, M.D. Learn more about our memberships hereEarn 1.25 CMEs: Navigating Insomnia in Major Depressive Disorder: Advances in ManagementOther Pharmacologic Interventions for Insomnia

In this episode, we explore the potential of fish oil as an adjunct to cognitive–behavioral therapy for treating depression in youth. Can this combination enhance treatment outcomes, or is cognitive–behavioral therapy alone just as effective? Join us as we dive into this intriguing study. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership hereEarn 0.5 CMEs: CAP Smart Takes Vol. 16Is Fish Oil Effective in Youth Depression?

In this episode, we explore the use of benzodiazepines and nonbenzodiazepine hypnotics for managing insomnia in major depressive disorder. How do these medications work, and what are the key considerations when prescribing them? Join us as we navigate the complexities of pharmacologic interventions for insomnia. Faculty: Amit Chopra, M.D. Host: Richard Seeber, M.D. Learn more about our memberships hereEarn 1.25 CME: Navigating Insomnia in Major Depressive Disorder: Advances in ManagementPharmacologic Interventions for Insomnia: Benzodiazepines and Non-Benzodiazepine Hypnotics

In this episode, we explore the safety of antipsychotics in patients with liver disease. How can psychiatrists navigate the risk–benefit balance when treating medically complex individuals? Dr. Sydney LeFay discusses key insights from a recent review article, guiding antipsychotic selection and monitoring. Faculty: Sydney LeFay, D.O. Host: Richard Seeber, M.D. Learn more about our membership hereEarn 0.75 CMEs: Quick Take Vol. 56Antipsychotic Safety in Liver Disease

In this episode, we explore the complex relationship between insomnia and major depressive disorder. How does insomnia impact the course and treatment of depression? Join us as we dive into the neurobiology and clinical implications of this fascinating topic with expert Dr. Amit Chopra. Faculty: Amit Chopra, M.D. Host: Richard Seeber, M.D. Learn more about our memberships hereEarn 1.25 CME: Navigating Insomnia in Major Depressive Disorder: Advances in ManagementUnderstanding the Relationship Between Insomnia Disorder and MDD

In this episode, we explore the long-term effects of ADHD medication use during pregnancy on children's development. Can continuing treatment pose risks, or is it safer than previously thought? Join us as we dive into a groundbreaking Danish study that sheds light on this critical question. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership hereEarn 0.5 CMEs: CAP Smart Takes Vol. 16In Utero Exposure to ADHD Medication and Long-Term Offspring Outcomes

In this episode, we explore the growing evidence for nonpharmacologic therapies in managing fibromyalgia symptoms. Could a combination of exercise, cognitive–behavioral therapy, and integrative approaches, like acupuncture or yoga, be the key to better outcomes for patients resistant to traditional treatments? Faculty: Daniel Clauw, M.D. Host: Richard Seeber, M.D. Learn more about our memberships hereEarn 0.75 CME: Nociplastic Pain Syndromes: Focus on FibromyalgiaNonpharmacologic Therapies for Fibromyalgia

In this episode, the editorial team of the Psychopharmacology Institute discusses 3 important topics presented at the APA Annual Meeting: Prescribing psychiatric medications during pregnancy, recent advances in clozapine treatment, and managing eating disorders, namely anorexia nervosa and bulimia nervosa. The episode covers the safety and dose adjustments for medications like SSRIs, lamotrigine, and lithium during pregnancy; early initiation and monitoring of clozapine; and effective treatments, including psychotherapy, olanzapine, and fluoxetine for eating disorders. Hosts: Flavio Guzman, M.D., Paz Badia, M.D., and Lorena Rodriguez, M.D.

In this episode, we discuss a new study on maternal depression, antidepressant use, and pregnancy complications. Can antidepressants during pregnancy harm the baby? Dr. Lauren Osborne helps us weigh the risks and benefits. Faculty: Lauren Osborne, M.D. Host: Richard Seeber, M.D. Learn more about our membership hereEarn 0.5 CMEs: Quick Take Vol. 56Neonatal and Pregnancy Complications Following Maternal Depression or Antidepressant Exposure

In this episode, we explore the most effective pharmacologic treatments for fibromyalgia, a complex nociplastic pain syndrome. Dr. Daniel Clauw shares his insights on the top drug classes for managing fibromyalgia and discusses why opioids should be avoided. Could the hyperactive endogenous opioid system in fibromyalgia patients explain the ineffectiveness of opioids? Faculty: Daniel Claw, M.D. Host: Richard Seeber, M.D. Learn more about our memberships hereEarn 0.75 CME: Nociplastic Pain Syndromes: Focus on FibromyalgiaPharmacologic Therapies for Fibromyalgia

In this episode, we explore the use of antipsychotic medication in treating children and adolescents with anorexia nervosa. Can these medications play a role in promoting weight gain and reducing comorbid symptoms? Or do the risks outweigh the potential benefits in this vulnerable population? Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership hereEarn 0.5 CME: CAP Smart Takes Vol. 15Antipsychotics in the Treatment of Youth With Anorexia Nervosa

In this episode, we dive into the diagnosis of fibromyalgia, a common nociplastic pain syndrome. We explore how to assess widespread pain and associated symptoms and how to understand fibromyalgia as a spectrum rather than a binary diagnosis. How can this nuanced approach help us tailor treatment strategies? Faculty: Daniel Clauw, M.D. Host: Richard Seeber, M.D. Learn more about our memberships hereEarn 0.75 CME: Nociplastic Pain Syndromes: Focus on FibromyalgiaDiagnosing Fibromyalgia

In this episode, we delve into the potential for irreversible sexual dysfunction after SSRI use, based on a large-scale Israeli study. Could a few months or even days of antidepressant treatment lead to permanent erectile issues? Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D. Learn more about our membership hereEarn 0.5 CMEs: Quick Take Vol. 55Risk of Irreversible Post‑SSRI Sexual Dysfunction With Antidepressants

In this episode, we discuss the management of common adverse effects associated with clozapine treatment, including myocarditis, cardiomyopathy, tachycardia, orthostatic hypotension, and metabolic syndrome. How can clinicians mitigate these risks while optimizing treatment outcomes for patients with treatment-resistant schizophrenia? Faculty: Brian Miller, M.D. Host: Richard Seeber, M.D. Learn more about our memberships hereEarn 1.25 CME: Clozapine: Management and ChallengesManaging Cardiac and Metabolic Adverse Effects of Clozapine

In this episode, we explore relapse prevention strategies for youth with depression and anxiety disorders. Are there effective ways to reduce the risk and prolong the time to relapse? Dr. David Rosenberg discusses the findings of a recent meta-analysis and systematic review on this crucial topic. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership hereEarn 0.5 CMEs: CAP Smart Takes Vol. 15Relapse Prevention Strategies for Depression and Anxiety in Remitted Youth

In this episode, we navigate the complexities of initiating and optimizing clozapine treatment for patients with treatment-resistant schizophrenia. How do you chart the course for successful clozapine therapy while managing side effects and drug interactions? Join us as Dr. Brian Miller shares his expertise and valuable psychopharmacology pearls. Faculty: Brian Miller, M.D. Host: Richard Seeber, M.D. Learn more about our memberships hereEarn 1.25 CMEs: Clozapine: Management and ChallengesInitiating and Optimizing Clozapine

In this episode, we discuss the prevalence of smoking among people with psychosis, based on recent findings from the PATH study. Dr. Oliver Freudenreich shares insights on how clinicians can prioritize smoking cessation in this population. How can we bridge the health outcome disparities faced by our patients with psychosis? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership hereEarn 0.75 CMEs: Quick Take Vol. 55Tobacco Use, Nicotine Dependence, and Cessation Among Adults with Psychosis